UK markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3000+0.0100 (+0.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.2900
Open3.2500
Bid3.2000 x 2200
Ask3.2900 x 1800
Day's range3.1900 - 3.3750
52-week range1.0100 - 9.0200
Volume963,012
Avg. volume2,495,633
Market cap321.751M
Beta (5Y monthly)2.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript
    Motley Fool

    Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation fourth-quarter and year-end 2020 financial results and corporate update conference call. Good morning, and thank you for joining the Arbutus Biopharma fourth-quarter 2020 conference call and webcast. On the call today are Bill Collier, president and chief executive officer; Dr. Gaston Picchio, chief development officer; Dr. Michael Sofia, chief scientific officer; and Dave Hastings, chief financial officer.

  • Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

    Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
    Zacks

    Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?

    Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.